Unzyme Laboratories announces that the VenoPulse Array has achieved all primary endpoints in its pivotal Phase III clinical trial. These exceptional results support regulatory submissions planned for Q4 2024 and position VenoPulse for commercial availability in 2025.
Trial Results
The PULSE-3 trial enrolled 2,341 participants across 18 clinical sites in Europe and North America. Results demonstrate significant improvements across all measured parameters:
Primary Endpoints:
- Peripheral circulation improvement: 47% average enhancement (p<0.001)
- Exercise tolerance: 39% improvement in standardized testing
- Recovery acceleration: 52% reduction in post-exertion recovery time
Safety Profile:
- No device-related serious adverse events
- Mild procedural discomfort reported by 8% of participants (resolved within 48 hours)
- 97% participant satisfaction with outcomes
“These results exceed our projections,” said Dr. Yuki Tanaka, Principal Investigator. “VenoPulse doesn’t just improve circulation—it transforms it. We’re seeing benefits that fundamentally enhance physical capability.”
The VenoPulse Advantage
VenoPulse Array enhances circulatory function through a network of biocompatible components that optimize blood flow throughout the peripheral vascular system. Unlike pharmacological approaches that provide temporary effects, VenoPulse delivers sustained enhancement through permanent integration.
Key advantages include:
- Improved oxygen and nutrient delivery to extremities
- Enhanced waste product clearance from active tissues
- Reduced cardiovascular strain during exertion
- Sustained benefits without ongoing medication
Clinical Implications
The applications for enhanced peripheral circulation span multiple domains:
- Athletic Performance: Sustained output, faster recovery, improved endurance
- Occupational Enhancement: Extended physical capability for demanding professions
- Age-Related Decline: Restoration of circulatory function to youthful parameters
- Rehabilitation: Accelerated recovery from injury or surgery
Path to Availability
Regulatory submissions will proceed immediately, with European CE marking anticipated in early 2025 and FDA clearance expected by mid-2025. Commercial availability will follow through our established clinical networks.
Individuals interested in VenoPulse should monitor our products page for availability updates or contact our clinical team to discuss eligibility.
Acknowledgments
We extend profound gratitude to our trial participants, clinical partners, and research teams. Your commitment advances the boundaries of human circulatory capability.
The heart of enhancement beats stronger.